Lancet publishes phase-3 trial data of Zydus' Covid vaccine ZyCoV-D

According to Zydus, the plug-and-play technology of the vaccine equips it to adapt to the rapidly mutating SARS COV-2 virus.

Zydus Lifesciences on Friday announced that the safety and efficacy analysis data from phase III clinical trial of its Plasmid DNA Covid-19 vaccine ZyCoV-D has been peer reviewed and published in The Lancet, a reputed and well known medical journal.

The double blind, placebo controlled, randomised Phase III clinical trial of the world’s first plasmid DNA vaccine, ZyCoV-D was one of the largest trials for a Covid-19 vaccine in India and was conducted on over 28,000 healthy adult volunteers at over 50 sites across the country.

An intradermal vaccine to be administered in three doses using the PharmaJet